Pfizer: Carcinoma, Non-Small-Cell Lung trials

The registry lists 158 Carcinoma, Non-Small-Cell Lung studies with Pfizer as lead sponsor. 15 are open to participants now and 72 have results posted.

Phase 1 69Phase 2 58Phase 3 18Phase 4 4No phase 22(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.WithdrawnNCT06075615
• A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerActive, not recruitingNCT06012435Phase 3
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2Active, not recruitingNCT06003231Phase 2
• A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsTerminatedNCT05983133Phase 1
• Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.WithdrawnNCT05905341Phase 1
• A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsTerminatedNCT05571839Phase 1
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsActive, not recruitingNCT05538130Phase 1
• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.Active, not recruitingNCT05355701Phase 1
• PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsTerminatedNCT05233436Phase 1
• A Study of SGN-ALPV in Advanced Solid TumorsTerminatedNCT05229900Phase 1
• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsTerminatedNCT05194072Phase 1
• Crizotinib Continuation Clinical StudyActive, not recruitingNCT05160922Phase 4
• Lorlatinib Continuation StudyActive, not recruitingNCT05144997Phase 4
• A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerWithdrawnNCT04889495
• Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.CompletedNCT04881045Phase 1
• PF-07284892 in Participants With Advanced Solid TumorsTerminatedNCT04800822Phase 1
• A Study of SGN-STNV in Advanced Solid TumorsTerminatedNCT04665921Phase 1
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2
• Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
• A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
• A Study of SGN-CD228A in Advanced Solid TumorsTerminatedNCT04042480Phase 1
• A Safety Study of SGN-CD47M in Patients With Solid TumorsTerminatedNCT03957096Phase 1
• Safety and Efficacy of LorbrenaCompletedNCT03844464
• Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsActive, not recruitingNCT03485209Phase 2
• Safety and Efficacy of Xalkori ROS1CompletedNCT03375242
• Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male VolunteersCompletedNCT03184168Phase 1
• Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 PositiveNo longer availableNCT03178071
• A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsTerminatedNCT02952989Phase 1
• Crizotinib Expanded Access Protocol For ROS1 Positive NSCLCNo longer availableNCT02824094
• Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
• A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung CancerWithdrawnNCT02297425Phase 2
• Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLCWithdrawnNCT02109653Phase 2
• A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung CancerWithdrawnNCT01500824Phase 2
• Study of PX-866 and Docetaxel in Solid TumorsCompletedNCT01204099Phase 1/2
• A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male VolunteersCompletedNCT01034748Phase 1
• A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804TerminatedNCT00971191Phase 1
• Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung CancerWithdrawnNCT00907504Phase 3
• Study Of SU011248 In Combination With Docetaxel In Patients With Advanced CancerCompletedNCT00712504Phase 1
• A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid TumorsCompletedNCT00528619Phase 1
• Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung CancerCompletedNCT00321815Phase 2
• Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung CancerTerminatedNCT00321308Phase 2
• Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLCTerminatedNCT00313768Phase 2
• Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLCTerminatedNCT00254904Phase 3
• Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT00254891Phase 3
• MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung CancerTerminatedNCT00174369Phase 2
• PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC PatientsCompletedNCT00174356Phase 1
• Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung CancerCompletedNCT00139711Phase 2
• Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung CancerCompletedNCT00092001Phase 2
• FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung CarcinomaCompletedNCT00086333Phase 2
• CPG 7909 Injection in Non-Small Cell Lung CancerCompletedNCT00070629Phase 2
• Study Evaluating EKB-569 in Advanced Non-Small Cell Lung CancerCompletedNCT00067548Phase 2
• Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based TherapyCompletedNCT00063219Phase 2
• Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung CarcinomaCompletedNCT00051571Phase 2
• PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)CompletedNCT00043368Phase 2
• Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)CompletedNCT00034957Phase 2
• A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic CancerCompletedNCT00034827Phase 2
• Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung CancerCompletedNCT00005093Phase 3
• Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung CancerCompletedNCT00004199Phase 3